279 related articles for article (PubMed ID: 9151914)
1. Factors associated with survival exceeding 5 years after transcatheter arterial embolization for hepatocellular carcinoma.
Yoshioka H; Sato M; Sonomura T; Terada M; Kishi K; Yoshikawa A
Semin Oncol; 1997 Apr; 24(2 Suppl 6):S6-29-S6-37. PubMed ID: 9151914
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors in resected hepatocellular carcinomas and therapeutic value of transcatheter arterial embolization for recurrences.
Kimura H; Yabushita K; Konishi K; Maeda K; Kuroda Y; Tsuji M; Demachi H; Miwa A
Int Surg; 1998; 83(2):146-9. PubMed ID: 9851333
[TBL] [Abstract][Full Text] [Related]
3. Prospective and randomized trial of lipiodol-transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: a comparison of epirubicin and doxorubicin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan.
Kawai S; Tani M; Okamura J; Ogawa M; Ohashi Y; Monden M; Hayashi S; Inoue J; Kawarada Y; Kusano M; Kubo Y; Kuroda C; Sakata Y; Shimamura Y; Jinno K; Takahashi A; Takayasu K; Tamura K; Nagasue N; Nakanishi Y; Makino M; Masuzawa M; Yumoto Y; Mori T; Oda T
Semin Oncol; 1997 Apr; 24(2 Suppl 6):S6-38-S6-45. PubMed ID: 9151915
[TBL] [Abstract][Full Text] [Related]
4. [A comparison of patients with hepatocellular carcinoma between a short-term (less than 6 months) survival group and a long-term (over 24 months) survival group after treatment with transcatheter arterial chemoembolization].
Kang IK; Kim SW; Hahn SH; Cho SC; Gham CW; Lee DH
Taehan Kan Hakhoe Chi; 2002 Jun; 8(2):189-200. PubMed ID: 12499805
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcomes of transcatheter arterial chemoembolization with autologous blood clot for unresectable hepatocellular carcinoma.
Gunji T; Kawauchi N; Akahane M; Watanabe K; Kanamori H; Ohnishi S
Int J Oncol; 2002 Aug; 21(2):427-32. PubMed ID: 12118341
[TBL] [Abstract][Full Text] [Related]
6. Chemoembolization for hepatocellular carcinoma: multivariate analysis of predicting factors for tumor response and survival in a 362-patient cohort.
Hu HT; Kim JH; Lee LS; Kim KA; Ko GY; Yoon HK; Sung KB; Gwon DI; Shin JH; Song HY
J Vasc Interv Radiol; 2011 Jul; 22(7):917-23. PubMed ID: 21571545
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for death in 224 cases of hepatocellular carcinoma after transcatheter arterial chemoembolization.
Hiraoka A; Horiike N; Yamashita Y; Koizumi Y; Doi H; Yamamoto Y; Ichikawa S; Hasebe A; Yano M; Miyamoto Y; Ninomiya T; Ootani H; Takamura K; Kawasaki H; Otomi Y; Kogame M; Sogabe I; Ishimaru Y; Kashihara K; Miyagawa M; Hirooka M; Hiasa Y; Matsuura B; Michitaka K; Onji M
Hepatogastroenterology; 2009; 56(89):213-7. PubMed ID: 19453060
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of tumor pressure as a prognostic factor in cases of hepatocellular carcinoma where the diameter of the tumor is 3 cm or less.
Ueki T; Sakaguchi S; Miyajima Y; Hatono N; Tohara K; Nakabayashi S; Yao T; Kokawa H; Hirano M; Okumura M
Cancer; 2002 Aug; 95(3):596-604. PubMed ID: 12209753
[TBL] [Abstract][Full Text] [Related]
9. Transcatheter arterial chemoembolization therapy combined with percutaneous ethanol injection for unresectable large hepatocellular carcinoma: an evaluation of the local therapeutic effect and survival rate.
Dohmen K; Shirahama M; Shigematsu H; Miyamoto Y; Torii Y; Irie K; Ishibashi H
Hepatogastroenterology; 2001; 48(41):1409-15. PubMed ID: 11677976
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with transcatheter arterial embolization and percutaneous ethanol injection for advanced hepatocellular carcinoma.
Koda M; Okamoto K; Miyoshi Y; Kato S; Murawaki Y; Horie Y; Suou T; Kawasaki H
Hepatogastroenterology; 1994 Feb; 41(1):25-9. PubMed ID: 8175109
[TBL] [Abstract][Full Text] [Related]
11. Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma.
Li B; Yu J; Wang L; Li C; Zhou T; Zhai L; Xing L
Am J Clin Oncol; 2003 Aug; 26(4):e92-9. PubMed ID: 12902905
[TBL] [Abstract][Full Text] [Related]
12. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients.
Takayasu K; Arii S; Ikai I; Omata M; Okita K; Ichida T; Matsuyama Y; Nakanuma Y; Kojiro M; Makuuchi M; Yamaoka Y;
Gastroenterology; 2006 Aug; 131(2):461-9. PubMed ID: 16890600
[TBL] [Abstract][Full Text] [Related]
13. [The treatment of hepatocellular carcinoma by chemoembolization].
Marchiori L; Mansueto GC; Nifosi F; Bortolasi L; Dal Dosso I; Facci E; Perus G; Nicoli N
Chir Ital; 1994; 46(1):17-22. PubMed ID: 8025966
[TBL] [Abstract][Full Text] [Related]
14. The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction. A prospective controlled study.
Lee HS; Kim JS; Choi IJ; Chung JW; Park JH; Kim CY
Cancer; 1997 Jun; 79(11):2087-94. PubMed ID: 9179054
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of transcatheter arterial embolization in terms of serum alpha-fetoprotein doubling time in hepatocellular carcinoma].
Kanno T; Harihara S; Kim K; Kimura S; Tamori A; Kuroki T; Mizoguchi Y; Kobayashi K; Monna T; Nakamura K
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 1):683-7. PubMed ID: 2451472
[TBL] [Abstract][Full Text] [Related]
16. The role of transcatheter arterial embolization in patients with resectable hepatocellular carcinoma: a nation-wide, multicenter study.
Huang YH; Chen CH; Chang TT; Chen SC; Wang SY; Lee PC; Lee HS; Lin PW; Huang GT; Sheu JC; Tsai HM; Chau GY; Chiang JH; Lui WY; Lee SD; Wu JC
Liver Int; 2004 Oct; 24(5):419-24. PubMed ID: 15482337
[TBL] [Abstract][Full Text] [Related]
17. Monitoring of lectin-reactive alpha-fetoproteins in patients with hepatocellular carcinoma treated using transcatheter arterial embolization.
Yamashita F; Tanaka M; Satomura S; Tanikawa K
Eur J Gastroenterol Hepatol; 1995 Jul; 7(7):627-33. PubMed ID: 8590157
[TBL] [Abstract][Full Text] [Related]
18. [Stage III, IV hepatocellular carcinoma patients surviving more than five years after transcatheter chemoembolization].
Nakamura H; Mitani T; Murakami T; Hashimoto T; Nakanishi K; Maeshima S; Tsuda K; Tomoda K; Hori S; Kozuka T
Gan To Kagaku Ryoho; 1992 Aug; 19(10 Suppl):1756-8. PubMed ID: 1326925
[TBL] [Abstract][Full Text] [Related]
19. [The clinical course of nodular type hepatocellular carcinomas after transcatheter arterial embolization (TAE) therapy].
Suyama Y; Kitagawa Y; Horishi M; Shizumi Y; Yashige H; Fujii H; Miyoshi M
Gan No Rinsho; 1989 Aug; 35(9):983-9. PubMed ID: 2475651
[TBL] [Abstract][Full Text] [Related]
20. Indication of chemoembolization therapy without gelatin sponge for hepatocellular carcinoma.
Suzuki M; Suzuki H; Yamamoto T; Mamada Y; Mizuno H; Tominaga T; Suga M; Suemori S; Kato Y; Sato A; Yamanouchi E; Sakuyama K; Maeyama S; Shinagawa T; Okabe K
Semin Oncol; 1997 Apr; 24(2 Suppl 6):S6-110-S6-115. PubMed ID: 9151925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
